{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T05:30:18Z","timestamp":1772861418225,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:00:00Z","timestamp":1735171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006392","name":"Centre Hospitalier Universitaire Vaudois","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["324730_192449"],"award-info":[{"award-number":["324730_192449"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["32003B_179273"],"award-info":[{"award-number":["32003B_179273"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["PCL8-FFS 32072"],"award-info":[{"award-number":["PCL8-FFS 32072"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jpba.2024.116612","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T19:49:45Z","timestamp":1733168985000},"page":"116612","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Highly sensitive ultra-high-performance liquid chromatography coupled with tandem mass spectrometry method for the multiplex analysis of levosimendan and its metabolites OR-1855 and OR-1896 in human plasma"],"prefix":"10.1016","volume":"255","author":[{"given":"St\u00e9phane","family":"Bertin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Versace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Mercier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amarande","family":"Murisier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geraldine","family":"Sauvain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Haefliger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois R.","family":"Girardin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria-Helena","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rapha\u00ebl","family":"Giraud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Buclin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent A.","family":"Decosterd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Choong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Livio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2024.116612_bib1","doi-asserted-by":"crossref","DOI":"10.15420\/cfr.2020.03","article-title":"Levosimendan efficacy and safety: 20 years of SIMDAX in clinical use","volume":"6","author":"Papp","year":"2020","journal-title":"Card. Fail. Rev."},{"key":"10.1016\/j.jpba.2024.116612_bib2","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1093\/eurheartj\/ehy600","article-title":"Treatments targeting inotropy","volume":"40","author":"Maack","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jpba.2024.116612_bib3","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ejps.2007.08.003","article-title":"Pharmacokinetics and excretion balance of OR-1896, a pharmacologically active metabolite of levosimendan, in healthy men","volume":"32","author":"Puttonen","year":"2007","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2024.116612_bib4","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ejps.2004.07.005","article-title":"Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators","volume":"23","author":"Antila","year":"2004","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2024.116612_bib5","first-page":"87","article-title":"Pharmacokinetic variability of beta-lactams in critically ill patients: a narrative review","volume":"39","author":"Boidin","year":"2020","journal-title":"Anaesth. Crit. Care Pain. Med."},{"key":"10.1016\/j.jpba.2024.116612_bib6","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1001\/jama.2019.9302","article-title":"Extracorporeal life support for adults with respiratory failure and related indications: a review","volume":"322","author":"Brodie","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jpba.2024.116612_bib7","doi-asserted-by":"crossref","first-page":"741.e9","DOI":"10.1016\/j.jcrc.2012.02.013","article-title":"Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation","volume":"27","author":"Shekar","year":"2012","journal-title":"J. Crit. Care"},{"key":"10.1016\/j.jpba.2024.116612_bib8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s44158-021-00030-7","article-title":"Levosimendan in intensive care and emergency medicine: literature update and expert recommendations for optimal efficacy and safety","volume":"2","author":"Girardis","year":"2022","journal-title":"J. Anesth. Analg. Crit. Care"},{"key":"10.1016\/j.jpba.2024.116612_bib9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40262-022-01199-y","article-title":"Population pharmacokinetics of levosimendan and its metabolites in critically Ill neonates and children supported or not by extracorporeal membrane oxygenation","volume":"62","author":"Bourgoin","year":"2023","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jpba.2024.116612_bib10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1161\/01.CIR.0000043245.00859.11","article-title":"Sustained Hemodynamic Effects of Intravenous Levosimendan","volume":"107","author":"Kivikko","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jpba.2024.116612_bib11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejheart.2006.04.012","article-title":"Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure","volume":"9","author":"Lilleberg","year":"2007","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.jpba.2024.116612_bib12","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1186\/s13054-019-2704-2","article-title":"Prophylactic use of levosimendan in pediatric patients undergoing cardiac surgery: a prospective randomized controlled trial","volume":"23","author":"Wang","year":"2019","journal-title":"Crit. Care"},{"key":"10.1016\/j.jpba.2024.116612_bib13","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.3390\/pharmaceutics14071454","article-title":"Simultaneous LC-ESI-MS\/MS quantification of levosimendan and its metabolites for therapeutic drug monitoring of cardiac surgery patients","volume":"14","author":"Kipka","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jpba.2024.116612_bib14","doi-asserted-by":"crossref","first-page":"815","DOI":"10.3390\/ph16060815","article-title":"Monitoring of levosimendan administration in patients with pulmonary hypertension undergoing cardiac surgery and effect of two different dosing schemes on hemodynamic and echocardiographic parameters","volume":"16","author":"Ftikos","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jpba.2024.116612_bib15","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1002\/rcm.3046","article-title":"A strategy for high-throughput analysis of levosimendan and its metabolites in human plasma samples using sequential negative and positive ionization liquid chromatography\/tandem mass spectrometric detection","volume":"21","author":"Zhang","year":"2007","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.jpba.2024.116612_bib16","first-page":"1053","article-title":"Determination of levosimendan and its main metabolites in human plasma with HPLC-MS\/MS method","volume":"43","author":"Li","year":"2008","journal-title":"Acta Pharm. Sin."},{"key":"10.1016\/j.jpba.2024.116612_bib17","unstructured":"European Medicines Agency, ICH guideline M10 on bioanalytical method validation and study sample analysis, 2022. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-m10-bioanalytical-method-validation-step-5_en.pdf\u3009 (Accessed 27 April 2023)."},{"key":"10.1016\/j.jpba.2024.116612_bib18","unstructured":"U.S Food and Drug Administration, Bioanalytical Method Validation Guidance for Industry, 2018. \u3008https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf\u3009 (Accessed 27 April 2023)."},{"key":"10.1016\/j.jpba.2024.116612_bib19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/0091270002042001005","article-title":"Pharmacodynamics and Safety of a New Calcium Sensitizer, Levosimendan, and Its Metabolites during an Extended Infusion in Patients with Severe Heart Failure","volume":"42","author":"Kivikko","year":"2002","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2024.116612_bib20","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0003-2670(99)00106-3","article-title":"The SFSTP guide on the validation of chromatographic methods for drug bioanalysis: from the Washington Conference to the laboratory","volume":"391","author":"Hubert","year":"1999","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.jpba.2024.116612_bib21","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0731-7085(03)00182-1","article-title":"An analysis of the SFSTP guide on validation of chromatographic bioanalytical methods: progresses and limitations","volume":"32","author":"Boulanger","year":"2003","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116612_bib22","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jpba.2007.06.032","article-title":"Harmonization of strategies for the validation of quantitative analytical procedures","volume":"45","author":"Hubert","year":"2007","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116612_bib23","first-page":"169","article-title":"M\u00e9thodes chromatographiques de dosage dans les milieux biologiques: strat\u00e9gie de validation - Rapport d\u2019une commission SFSTP","volume":"7","author":"Chapuzet","year":"1997","journal-title":"STP Pharma Prat."},{"key":"10.1016\/j.jpba.2024.116612_bib24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.chroma.2007.03.111","article-title":"Analysis of recent pharmaceutical regulatory documents on analytical method validation","volume":"1158","author":"Rozet","year":"2007","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2024.116612_bib25","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s11095-007-9242-3","article-title":"A total error approach for the validation of quantitative analytical methods","volume":"24","author":"Hoffman","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jpba.2024.116612_bib26","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.chroma.2007.02.021","article-title":"Validation of analytical methods based on accuracy profiles","volume":"1158","author":"Feinberg","year":"2007","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2024.116612_bib27","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.trac.2018.04.013","article-title":"From method validation to result assessment: Established facts and pending questions","volume":"105","author":"Rudaz","year":"2018","journal-title":"TrAC Trends Anal. Chem."},{"key":"10.1016\/j.jpba.2024.116612_bib28","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s00216-004-2791-y","article-title":"New advances in method validation and measurement uncertainty aimed at improving the quality of chemical data","volume":"380","author":"Feinberg","year":"2004","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jpba.2024.116612_bib29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.chroma.2014.05.047","article-title":"Derivation of uncertainty functions from validation studies in biological fluids: Application to the analysis of caffeine and its major metabolites in human plasma samples","volume":"1353","author":"Gassner","year":"2014","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2024.116612_bib30","unstructured":"European Medicines Agency, ICH Q2(R2) Guideline on validation of analytical procedures - Step 5, 2013. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-q2r2-guideline-validation-analytical-procedures-step-5-revision-1_en.pdf\u3009(Accessed March 11, 2024)."},{"key":"10.1016\/j.jpba.2024.116612_bib31","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1600-0773.1996.tb00211.x","article-title":"Arylamine N-acetyltransferase in erythrocytes of cystic fibrosis patients","volume":"78","author":"Risch","year":"1996","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.jpba.2024.116612_bib32","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0090-9556(25)07325-8","article-title":"Inhibition of Human Red Blood Cell N-acetyltransferase","volume":"21","author":"Voice","year":"1993","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jpba.2024.116612_bib33","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/0006-2952(92)90373-Q","article-title":"Arylamine N-acetyltransferase in human red blood cells","volume":"44","author":"Ward","year":"1992","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jpba.2024.116612_bib34","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.bcp.2018.08.034","article-title":"Expression and genotype-dependent catalytic activity of N-acetyltransferase 2 (NAT2) in human peripheral blood mononuclear cells and its modulation by Sirtuin 1","volume":"156","author":"Salazar-Gonz\u00e1lez","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jpba.2024.116612_bib35","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1124\/dmd.106.014621","article-title":"Identification of N-Acetyltransferase 2 (NAT2) transcription start sites and quantitation of NAT2-specific mRNA in human tissues","volume":"35","author":"Husain","year":"2007","journal-title":"Drug Metab. Dispos."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170852400654X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170852400654X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T12:19:04Z","timestamp":1769689144000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073170852400654X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":35,"alternative-id":["S073170852400654X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116612","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Highly sensitive ultra-high-performance liquid chromatography coupled with tandem mass spectrometry method for the multiplex analysis of levosimendan and its metabolites OR-1855 and OR-1896 in human plasma","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116612","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"116612"}}